GlassScriptPhysician profile
Jennifer Lambert
NPI 1730850835
$9,214.36
in general payments reported to CMS, 2019-2025
36 companies · $2,776 in 2025
The $2,776 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $2,213 · 2023: $2,541 · 2024: $1,685 · 2025: $2,776.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,869 · Education: $132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,869.31 |
| Education | $132.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,998.84 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,071.25 | 2022-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $767.52 | 2022-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $420.16 | 2022-2025 | Xifaxan, Trulance, Relistor |
| Ardelyx, INC. | $364.33 | 2022-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $362.76 | 2022-2024 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $335.20 | 2022-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $326.56 | 2024-2025 | Voquezna |
| Ferring Pharmaceuticals INC. | $323.20 | 2022-2025 | Rebyota, Clenpiq |
| Redhill Biopharma INC. | $211.08 | 2022-2023 | Aemcolo, Talicia, Movantik |
| Ironwood Pharmaceuticals, INC | $203.04 | 2022-2024 | Linzess |
| Genzyme Corporation | $186.42 | 2022-2025 | |
| Celgene Corporation | $168.90 | 2022-2023 | Zeposia |
| Braintree Laboratories, INC. | $160.41 | 2024-2025 | Suflave, Sutab |
| Lilly USA, LLC | $157.64 | 2024-2025 | Omvoh |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $128.62 | 2024-2025 | Iqirvo, Bylvay |
| Janssen Scientific Affairs, LLC | $126.80 | 2024 | Tremfya |
| Vivus LLC | $87.68 | 2022-2023 | Qsymia |
| Aimmune Therapeutics, INC. | $87.21 | 2024-2025 | Zenpep, Vowst |
| Madrigal Pharmaceuticals | $85.49 | 2024-2025 | Rezdiffra, Resmetirom |
| Daiichi Sankyo INC. | $76.99 | 2022-2023 | Injectafer |
| Evoke Pharma, INC. | $66.26 | 2025 | |
| Pfizer INC. | $65.14 | 2024-2025 | |
| Qol Medical, LLC | $64.17 | 2023-2024 | Sucraid, Sucraid |
| Celltrion USA INC. | $57.96 | 2024-2025 | Vegzelma, Zymfentra |
| Organon LLC | $53.97 | 2023-2024 | Renflexis, Hadlima |
| Amgen INC. | $47.98 | 2023 | Avsola, Amjevita |
| Fresenius Kabi USA, LLC | $42.37 | 2024 | Idacio |
| E.R. Squibb & Sons, L.L.C. | $32.11 | 2023 | Zeposia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.49 | 2023 | |
| Alnylam Pharmaceuticals INC. | $25.65 | 2023 | Oxlumo |
| Amag Pharmaceuticals, INC. | $23.70 | 2022 | |
| Azurity Pharmaceuticals, INC. | $16.41 | 2025 | Suflave |
| Enterra Medical, INC. | $15.75 | 2024 | |
| Medtronic, INC. | $13.67 | 2023 | Nexpowder |
| Nestle Healthcare Nutrition INC. | $12.63 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Lambert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.